Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465323 | 1.00 | ALDH1A1 (0.44) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL19779412 | 0.96 | ALDH1A1 (0.43) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL21480155 | 0.96 | ALDH1A1 (0.43) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL21480154 | 0.96 | ALDH1A1 (0.43) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL8388967 | 0.92 | FUCA1 (0.44) | ALDH1A1FUCA1POLBGBA1OPRL1 | |
| SCHEMBL7386938 | 0.83 | SLC6A2 (0.49) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL7386941 | 0.83 | SLC6A2 (0.49) | ALDH1A1FUCA1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL4482745 | 0.82 | FUCA1 (0.46) | ALDH1A1FUCA1MEN1TSHRKMT2A | |
| SCHEMBL31325224 | 0.82 | FUCA1 (0.46) | ALDH1A1FUCA1MEN1TSHRKMT2A | |
| SCHEMBL7694829 | 0.79 | HTR2A (0.46) | CYP2D6CYP1A2CYP3A4MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270417-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | ALDH1A1 2750/4885FUCA1 2663/4885CYP2D6 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.